Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | butyrylcholinesterase | Starlite/ChEMBL | References |
Equus caballus | Cholinesterase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | BC026374 protein S09 family | Cholinesterase | 574 aa | 642 aa | 34.4 % |
Echinococcus multilocularis | BC026374 protein (S09 family) | Cholinesterase | 574 aa | 636 aa | 34.9 % |
Onchocerca volvulus | Carnitine O-palmitoyltransferase 2, mitochondrial homolog | Cholinesterase | 574 aa | 554 aa | 36.1 % |
Loa Loa (eye worm) | hypothetical protein | Cholinesterase | 574 aa | 520 aa | 27.1 % |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | Cholinesterase | 574 aa | 590 aa | 25.1 % |
Brugia malayi | Carboxylesterase family protein | butyrylcholinesterase | 602 aa | 546 aa | 30.2 % |
Brugia malayi | Carboxylesterase family protein | Cholinesterase | 574 aa | 538 aa | 31.4 % |
Onchocerca volvulus | Cholinesterase | 574 aa | 586 aa | 27.1 % | |
Drosophila melanogaster | CG10175 gene product from transcript CG10175-RE | Cholinesterase | 574 aa | 547 aa | 29.4 % |
Onchocerca volvulus | Galectin homolog | Cholinesterase | 574 aa | 531 aa | 39.7 % |
Onchocerca volvulus | Cholinesterase | 574 aa | 578 aa | 25.3 % | |
Onchocerca volvulus | Molybdopterin synthase catalytic subunit homolog | Cholinesterase | 574 aa | 560 aa | 29.3 % |
Onchocerca volvulus | Putative nuclear protein | Cholinesterase | 574 aa | 572 aa | 40.9 % |
Schistosoma mansoni | gliotactin | Cholinesterase | 574 aa | 587 aa | 27.9 % |
Onchocerca volvulus | Cholinesterase | 574 aa | 551 aa | 29.9 % | |
Schistosoma japonicum | ko:K01050 cholinesterase [EC3.1.1.8], putative | Cholinesterase | 574 aa | 577 aa | 36.9 % |
Echinococcus granulosus | neuroligin | Cholinesterase | 574 aa | 492 aa | 24.4 % |
Loa Loa (eye worm) | hypothetical protein | Cholinesterase | 574 aa | 573 aa | 26.4 % |
Brugia malayi | Carboxylesterase family protein | Cholinesterase | 574 aa | 549 aa | 29.5 % |
Brugia malayi | Carboxylesterase family protein | Cholinesterase | 574 aa | 472 aa | 27.5 % |
Echinococcus multilocularis | neuroligin | Cholinesterase | 574 aa | 493 aa | 26.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | carboxylesterase 5A | 0.0164 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0164 | 0.5 | 0.5 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0164 | 0.5 | 0.5 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0164 | 0.5 | 0.5 |
Loa Loa (eye worm) | carboxylesterase | 0.0164 | 0.5 | 0.5 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0164 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0164 | 0.5 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0164 | 0.5 | 0.5 |
Brugia malayi | Carboxylesterase family protein | 0.0164 | 0.5 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0164 | 0.5 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0164 | 0.5 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0164 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 3.6 uM | Inhibition of equine serum BuChE using butyrylthiocholine iodide as substrate preincubated for 10 mins before substrate addition by Ellman's method | ChEMBL. | 22000936 |
IC50 (binding) | = 3.78 uM | Inhibition of human serum BuChE using butyrylthiocholine as substrate by Ellman's assay | ChEMBL. | 22000936 |
IC50 (binding) | > 100 uM | Inhibition of Electrophorus electricus AChE using acetylthiocholine iodide as substrate preincubated for 10 mins before substrate addition by Ellman's method | ChEMBL. | 22000936 |
IC50 (binding) | > 100 uM | Inhibition of human recombinant AChE using acetylthiocholine as substrate by Ellman's assay | ChEMBL. | 22000936 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.